Overview

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Status:
Withdrawn

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on matrix metalloproteinases, that infliximab therapy for such patients may reduce the likelihood of corneal ulceration, and hence extend the period of prosthesis retention and vision recovery.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Massachusetts Eye and Ear Infirmary

Treatments:

Infliximab